Back

Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Optimal management of acute heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Ranel Loutati

Sheba Medical Center, Ramat Gan (Israel)

5 More presentations in this session

Presentation thumbnail
Diuretic resistance and the efficacy of natriuresis-guided diuretic therapy in acute heart failure: a post-hoc analysis of the PUSH-AHF trial
Ms L. Zonneveld (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Barriers to mineralocorticoid receptor antagonists dose escalation in heart failure: Findings from the OPRA-HF Run-in period
Doctor C. Basic (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
Fluid management of acute decompensated heart failure subjects treated with reprieve decongestion management system
Doctor J. Nunez Villota (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of colchicine in myocardial infarction: an updated systematic review and meta-analysis
Doctor T. Warsi (Plymouth, GB)
Abstract Slides Video
Presentation thumbnail
Development and delivery of a multilingual online heart failure course for cardiology nurses: a collaborative initiative between ACNAP and the HFA
Mrs M. Simpson (Edinburgh, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Optimal management of acute heart failure
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Tricuspid regurgitation is a barrier to guideline-directed medical therapy implementation in patients with acute decompensated heart failure and reduced ejection fraction
thumbnail
Congress Presentation
DISCOVER SGLT2i - myocardial deformation and reverse remodelling after SGLT2 inhibitors
thumbnail
Congress Presentation
The impact of sodium glucose transporter 2 inhibitors on cardiac remodeling in a large cohort of unselected patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources